U.S. Markets closed

Ampio Pharmaceuticals, Inc. (AMPE)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.67+0.07 (+11.67%)
At close: 3:59PM EDT
People also watch
Full screen
Previous Close0.60
Bid0.58 x 400
Ask0.63 x 2600
Day's Range0.59 - 0.67
52 Week Range0.38 - 1.14
Avg. Volume331,185
Market Cap45.72M
PE Ratio (TTM)-3.24
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals6 months ago

    Colorado biotech's accountants express 'substantial doubt' about firm's future

    In a recent 10-K filing with the Securities and Exchange Commission, Douglas County-based Ampio (AMPE) said "a 'going concern' opinion could impair our ability to finance our operations through the sale of debt or equity securities or through bank financing. Ampio is developing Ampion, an anti-inflammatory drug designed to treat to severe pain associated with osteoarthritis of the knee , which company officials are excited about. In the history of the company, we have never been as close to realizing what we believe to be the full potential of Ampion, both from a regulatory perspective as well as commercial," said Michael Macaluso, chairman, and CEO, in a statement .

  • TheStreet.comlast year

    7 Stocks Under $10 That Could Make You a Lot of Money

    When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

  • Answering Two Most Important Questions Surrounding Ampio Pharmaceuticals Inc (AMPE)
    Insider Monkeylast year

    Answering Two Most Important Questions Surrounding Ampio Pharmaceuticals Inc (AMPE)

    Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) has recently reported topline from its PIVOT trial and the stock lost over 60% on the announcement last Thursday. From this decline alone, it’s clear that the company didn’t report anything great, but despite missing the primary endpoint in the trial, management is shooting for an approval on the data. What […]